EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Although targeted therapy is standard of care in a large subset of oncogenic addicted non-small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been feasible for all genomic alterations such as for those tumors harboring Epidermal Growth Factor Receptor (EGFR) exon 20 in...

Full description

Autores:

Remón, Jordi
Hendriks, Lizza E.L
Cardona-Mendoza, Andrés Felipe

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/4440

Acceso en línea:

http://hdl.handle.net/20.500.12495/4440
https://doi.org/10.1016/j.ctrv.2020.102105

Palabra clave:

EGFR exon 20 insertions
Poziotinib
TAK-788
Amivantamab
Osimertinib

Rights

openAccess

License

Acceso abierto